Fig. 5: SCD1 inhibitor sensitizes 5FU + CDDP-drug resistant gastric cancer to chemo-treatment and reduces tumor-initiating cells frequency.
From: ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer
a, b Functional assays investigating the effect of pharmacological inhibition of SCD1 using a SCD1 specific inhibitor SSI4 in GX006 parental and 5FU + CDDP resistant organoid lines. Comparisons include DMSO versus 5FU + CDDP versus SSI4 versus combination of 5FU + CDDP and SSI4 (COMBO) using Annexin V-PI apoptosis (a) and in vitro limiting dilution spheroid formation assays (b). c Schematic diagram of treatment regimen comparing GX006 parental and 5FU + CDDP resistant organoid lines treated with DMSO or 5FU + CDDP and in combination with vehicle or SSI4. d, e Volume (d) and weight (e) of tumors derived from the indicated treatment groups at end point. f Waterfall plot showing the response of each tumor in each treatment group at end point. g Ex vivo limiting dilution assay of HCC tumors harvested from each treatment group to evaluate tumor-initiating cell frequency. (a) n = 4 independent experiments; (b) n = 3 independent experiments; (c–e) n = 8 mice. Significance were calculated by (a, d) two-way ANOVA; (b, g) one-sided extreme limiting dilution analysis; (e, f) one-way ANOVA. Data were presented as mean ± standard deviation. COMBO for combination. ns for not significant. Source data are provided as a Source Data file. Illustration for (c) was created using BioRender.com.
